Talimogene laherparepvec Disease Interactions
There are 4 disease interactions with talimogene laherparepvec.
Talimogene laherparepvec (applies to talimogene laherparepvec) immunocompromised
Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
Talimogene laherparepvec is a live, attenuated herpes simplex virus. The use talimogene laherparepvec is contraindicated in patients who are immunocompromised as its administration in these patients may cause life-threatening disseminated herpetic infection.
Talimogene laherparepvec (applies to talimogene laherparepvec) immunodeficiency
Major Potential Hazard, Moderate plausibility. Applicable conditions: Lymphoma, Leukemia
Do not administer talimogene laherparepvec to patients with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.
Talimogene laherparepvec (applies to talimogene laherparepvec) autoimmune disorders
Moderate Potential Hazard, Moderate plausibility.
The use of talimogene laherparepvec may result in immune-mediated events. Exercise care when using this agent in patients with underlying autoimmune disease or before continuing treatment in those patients that have developed immune-mediated events. Close monitoring is recommended.
Talimogene laherparepvec (applies to talimogene laherparepvec) multiple myeloma
Moderate Potential Hazard, Moderate plausibility.
Plasmacytoma, in proximity to the injection site, has been reported after administration of talimogene laherparepvec in a patient with smoldering multiple myeloma. It is recommended to consider the risks and benefits of treatment in patients with multiple myeloma or in whom plasmacytoma develops during treatment. Close monitoring is recommended.
Switch to professional interaction data
Talimogene laherparepvec drug interactions
There are 302 drug interactions with talimogene laherparepvec.
Report options
More about talimogene laherparepvec
- talimogene laherparepvec consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer, such as melanoma, non-small cell lung cancer ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Opdualag
Opdualag (nivolumab and relatlimab-rmbw) is used for the treatment of unresectable or metastatic ...
Interferon alfa-2b
Interferon alfa-2b is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated ...
Dacarbazine
Dacarbazine is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.